Latest Science (My Take)
Following Rett Syndrome research and translating it into plain language. Everything on this page comes from Reverse Rett (RSRT) and IRSF (rettsyndrome.org). My takes are my own as a Rett parent, not a scientist.
Disclaimer: I am a parent, not a medical professional. Nothing on this page is medical advice. Always consult your child's neurologist before making any treatment decisions.
The Big Questions
Is there an approved treatment for Rett Syndrome?
Yes — as of March 2023. Trofinetide (Daybue) became the first FDA-approved treatment specifically for Rett Syndrome. It manages symptoms but does not correct the underlying MECP2 mutation. IRSF: Available Treatments ↗
Where do the gene therapy trials stand right now?
Two programs are in advanced trials as of mid-2026. TSHA-102 (Taysha) has FDA Breakthrough Therapy Designation and is in a pivotal trial. NGN-401 (Neurogene) completed enrollment of its Embolden™ registrational trial in March 2026. Both were built with RSRT funding. RSRT: Gene Therapy ↗
What is RSRT's goal?
RSRT's Roadmap to Cures 2.0 aims to have 3 genetic medicines in clinical trials by 2028, funded by raising $40 million over 4 years. They are funding six different genetic medicine approaches simultaneously — more shots on goal. RSRT: Roadmap to Cures ↗
Research Summaries
Sourced from Reverse Rett (RSRT) and IRSF. Each entry includes what the research is, where it stands, and my honest take as a Rett parent.
What the research says
In March 2023, the FDA approved Trofinetide (brand name Daybue, made by Acadia Pharmaceuticals) for Rett Syndrome in patients 2 years and older — the first treatment ever approved specifically for Rett Syndrome. IRSF funded the research that helped make this possible. Trofinetide is a synthetic analog of a naturally occurring brain compound. It does not correct the underlying MECP2 mutation, but clinical trials showed statistically significant improvements in core Rett symptoms. The most common side effects are diarrhea and vomiting.
My take as a Rett parent
This is genuinely historic. For decades there was nothing approved specifically for Rett. Trofinetide doesn't cure Rett or fix the MECP2 mutation, but having an FDA-approved treatment is a foundation. Every family's experience is different — the GI side effects are real and can be a barrier for some. But this opened the door.
What the research says
TSHA-102 delivers a shortened MECP2 mini-gene along with Taysha's miRARE platform technology, which regulates MECP2 expression to prevent dangerous overexpression. It is delivered via intrathecal injection into the cerebrospinal fluid. The mini-gene was developed by Adrian Bird, PhD, and the miRARE platform by Steve Gray, PhD — both through RSRT-funded consortia. In October 2025, TSHA-102 received FDA Breakthrough Therapy Designation. In August 2025, Taysha advanced to the REVEAL Pivotal Trial. Both adult and pediatric trials are active.
My take as a Rett parent
FDA Breakthrough Therapy Designation is a big deal — it means the FDA sees enough early promise to work closely with Taysha to speed up development. The fact that this was built on RSRT-funded science (Adrian Bird's lab, Steve Gray's lab) is a direct line from donations to clinical trials. Watching this one very closely.
What the research says
NGN-401 delivers a full-length MECP2 gene using Neurogene's EXACT (Expression Attenuation via Construct Tuning) technology to regulate protein levels and avoid toxicity from overexpression. It is administered via intracerebroventricular (ICV) injection. The program was developed by Stuart Cobb, PhD, with nearly $3 million in RSRT funding. In November 2025, Neurogene dosed the first participant in the Embolden™ registrational trial. By March 2026, the Embolden™ trial was fully enrolled — a major milestone.
My take as a Rett parent
Fully enrolled means all the participants are in and the trial is running. That's a huge step toward having real efficacy data. Two gene therapy programs now in registrational-level trials at the same time — that has never happened before for Rett. The community built this through years of fundraising and advocacy.
What the research says
In June 2026, RSRT announced a new partnership with Reverta to advance gene therapy for Rett Syndrome. This is part of RSRT's Roadmap to Cures 2.0 strategy, which aims to have 3 genetic medicines in clinical trials by 2028. RSRT's role is to fund, broker, and transition programs from academic labs to biopharma partners — filling the 'Valley of Death' gap that causes most discoveries to never reach patients.
My take as a Rett parent
RSRT keeps building the pipeline. The goal of 3 genetic medicines in trials by 2028 is ambitious, but they've already got two. Adding a third would mean even more shots on goal — and more chances that one of them works for our kids.
What the research says
In May 2026, RSRT published an article explaining what Intellia Therapeutics' CRISPR breakthrough means for Rett families. Intellia demonstrated a 'single shot that rewrites the code' — a one-time in vivo CRISPR gene editing treatment delivered systemically. While this was not a Rett-specific trial, the technology is directly relevant to the base editing, prime editing, and MECP2 reactivation approaches RSRT is funding for Rett Syndrome.
My take as a Rett parent
CRISPR advances in any disease can accelerate Rett research because the delivery and editing tools are shared across conditions. RSRT is already funding CRISPR-based approaches for Rett — this kind of external validation of the technology is encouraging.
What the research says
Every girl with Rett Syndrome has a healthy, working copy of MECP2 on her second X chromosome — it's just silenced by a normal process called X-inactivation. MECP2 Reactivation research aims to wake up that dormant healthy gene. RSRT funds this approach because it is relevant for all MECP2 mutations. IRSF also funds preclinical ASO (antisense oligonucleotide) work in this area — specifically Jeannie Lee, MD, PhD at Massachusetts General Hospital, who is developing ASO drugs to reactivate the silent MECP2 copy in mouse models and patient cells.
My take as a Rett parent
This is one of the most elegant ideas in Rett research — using what's already there. If it works, it's essentially a cure from within. We're still in preclinical stages, but RSRT and IRSF are both funding it, which means the scientific community takes it seriously.
What the research says
In March 2026, RSRT published 'RNA Trans-splicing Comes of Age,' highlighting significant progress in this approach. RNA Trans-splicing works by replacing mutated sections (exons) of the MECP2 gene's RNA with healthy versions — without touching the DNA itself. RSRT notes this approach is relevant for all MECP2 mutations. The article signals that this technology has matured enough to be taken seriously as a path toward clinical development.
My take as a Rett parent
The fact that RSRT is calling this approach 'coming of age' is meaningful — they don't hype things that aren't ready. This adds another potential path to treatment, which is exactly what the community needs.
What the research says
Many individuals with Rett Syndrome experience extreme sensitivity to sounds and touch, as well as heightened anxiety. IRSF is funding Crystal Engineer, PhD at the University of Texas at Dallas to test whether vagus nerve stimulation (VNS) paired with rehabilitation therapy can reduce sensory hypersensitivity and anxiety in a Rett rat model. VNS is already FDA-approved for epilepsy and depression. If effective in this study, it could offer a new therapy to improve sensory processing and quality of life.
My take as a Rett parent
VNS is already something many Rett families know — it's used for seizures. The idea that it might also help with sensory hypersensitivity and anxiety is interesting. This is the kind of research that could improve daily quality of life even before a cure arrives.
What the research says
The PRISM Study (Presymptomatic Rett Biomarkers Study of MECP2 Mutations), led by Mark Shen, PhD at UNC Chapel Hill and funded by IRSF, is studying early development in children with MECP2 mutations before classic Rett symptoms appear. For families who receive an early genetic diagnosis, this period can feel isolating and ambiguous. PRISM aims to identify early biomarkers that could guide earlier intervention and improve clinical trial design.
My take as a Rett parent
Early diagnosis is becoming more common as genetic testing improves. Understanding what's happening in the brain before symptoms fully emerge could be critical for timing future treatments. This study is building the foundation for that.
What the research says
In April 2026, RSRT announced $6.4 million in 2025 research awards to advance genetic medicines for Rett Syndrome. This funding supports multiple approaches across RSRT's Roadmap to Cures 2.0, including gene therapy, base editing, prime editing, MECP2 reactivation, RNA editing, and RNA trans-splicing. RSRT also announced a $1 million collaboration with Profluent to use artificial intelligence to advance gene editing for Rett (November 2025), and a partnership with CRISPR pioneer Jennifer Doudna's lab (January 2025).
My take as a Rett parent
This is where donations go. RSRT is methodically funding every promising approach — not betting everything on one. The AI collaboration with Profluent and the partnership with Jennifer Doudna's lab show they're pulling in the best minds in science, not just Rett specialists.
Stay Updated
I update this page as I learn more. For the most current research news, go straight to the source: